CERVARIX is a vaccine intended to protect against the diseases caused by Human Papillomavirus (HPV) types 16 and 18 infection. These diseases include:
- cervical cancer (cancer of the cervix i.e. lower part of the uterus or womb), vulvar cancer, vaginal cancer and anal cancer
- precancerous cervical, vulvar, vaginal and anal lesions (changes in cells that have a risk of turning into cancer).
CERVARIX will not protect against all types of Human Papillomavirus. Other HPV types can also cause cervical cancer. HPV types 16 and 18 are responsible for approximately 70% of cervical cancer cases. CERVARIX works by stimulating the production of antibodies against HPV types 16 and 18. These antibodies have been shown in clinical trials to protect women aged 15 years and older against HPV - 16 and 18 related diseases. The vaccine also stimulates the production of antibodies in 9 to 14 years old children and adolescents, and in 26 to 55 years old women. Although vaccination may protect you against cervical cancer, it is not a substitute for regular cervical screening. You should continue to follow your doctor’s advice on cervical smear/Pap test and preventative and protective measures. CERVARIX is not infectious and so, it cannot cause HPV related diseases. CERVARIX will not treat HPV related diseases already present at time of vaccination. As with all vaccines, CERVARIX may not fully protect all people who are vaccinated. CERVARIX will not protect against other diseases that are not caused by Human Papillomavirus. The duration of protection is currently unknown. In clinical trials, sustained protection has been observed for at least 9,4 years after the first dose. Long-term studies are ongoing to establish the duration of protection.